QL 1012
Alternative Names: QL-1012Latest Information Update: 14 Dec 2021
Price :
$50 *
At a glance
- Originator Qilu Pharmaceutical
- Class Follicle stimulating hormones; Infertility therapies; Pituitary gonadotropins; Recombinant fusion proteins
- Mechanism of Action Follicle stimulating hormone replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Female infertility
Most Recent Events
- 14 Dec 2021 No development reported - Phase-III for Female infertility in China (SC) (Qilu Pharmaceutical pipeline, December 2021)
- 17 Oct 2019 Qilu Pharmaceutical completes a phase III trial in Female infertility in China (SC) (NCT05149924)
- 31 Oct 2018 Phase-III clinical trials in Female infertility in China (SC) (NCT05149924)